Department of Anesthesiology and Intensive Care Medicine, University Hospital Wuerzburg, Germany.
Department of Anesthesiology and Intensive Care Medicine, University Hospital Wuerzburg, Germany.
Clin Nutr. 2022 Dec;41(12):3089-3095. doi: 10.1016/j.clnu.2021.03.001. Epub 2021 Mar 7.
BACKGROUND & AIMS: Vitamin D's pleiotropic effects include immune modulation, and its supplementation has been shown to prevent respiratory tract infections. The effectivity of vitamin D as a therapeutic intervention in critical illness remains less defined. The current study analyzed clinical and immunologic effects of vitamin D levels in patients suffering from coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS).
This was a single-center retrospective study in patients receiving intensive care with a confirmed SARS-CoV-2 infection and COVID-19 ARDS. 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D serum levels, pro- and anti-inflammatory cytokines and immune cell subsets were measured on admission as well as after 10-15 days. Clinical parameters were extracted from the patient data management system. Standard operating procedures included the daily administration of vitamin D via enteral feeding.
A total of 39 patients with COVID-19 ARDS were eligible, of which 26 were included in this study as data on vitamin D status was available. 96% suffered from severe COVID-19 ARDS. All patients without prior vitamin D supplementation (n = 22) had deficient serum levels of 25-hydroxyvitamin D. Vitamin D supplementation resulted in higher serum levels of 25-hydroxyvitamin D but not did not increase 1,25-dihydroxyvitamin D levels after 10-15 days. Clinical parameters did not differ between patients with sufficient or deficient levels of 25-hydroxyvitamin D. Only circulating plasmablasts were higher in patients with 25-hydroxyvitamin D levels ≥30 ng/ml (p = 0.029). Patients with 1,25-dihydroxyvitamin D levels below 20 pg/ml required longer mechanical ventilation (p = 0.045) and had a worse acute physiology and chronic health evaluation (APACHE) II score (p = 0.048).
The vast majority of COVID-19 ARDS patients had vitamin D deficiency. 25-hydroxyvitamin D status was not related to changes in clinical course, whereas low levels of 1,25-dihydroxyvitamin D were associated with prolonged mechanical ventilation and a worse APACHE II score.
维生素 D 的多种作用包括免疫调节,其补充已被证明可预防呼吸道感染。维生素 D 作为危重病治疗干预的有效性仍不明确。本研究分析了患有 2019 年冠状病毒病(COVID-19)引起的急性呼吸窘迫综合征(ARDS)的患者的维生素 D 水平的临床和免疫效应。
这是一项在重症监护病房接受治疗的 SARS-CoV-2 感染和 COVID-19 ARDS 患者的单中心回顾性研究。在入院时以及 10-15 天后测量了 25-羟维生素 D 和 1,25-二羟维生素 D 血清水平、促炎和抗炎细胞因子以及免疫细胞亚群。从患者数据管理系统中提取临床参数。标准操作规程包括通过肠内喂养每日给予维生素 D。
共有 39 名 COVID-19 ARDS 患者符合条件,其中 26 名纳入本研究,因为有维生素 D 状态的数据。96%的患者患有严重的 COVID-19 ARDS。所有未接受过维生素 D 补充的患者(n=22)均有 25-羟维生素 D 缺乏症。维生素 D 补充后血清 25-羟维生素 D 水平升高,但 10-15 天后 1,25-二羟维生素 D 水平并未升高。25-羟维生素 D 水平充足或不足的患者的临床参数无差异。仅循环浆母细胞在 25-羟维生素 D 水平≥30ng/ml 的患者中更高(p=0.029)。1,25-二羟维生素 D 水平低于 20pg/ml 的患者需要更长时间的机械通气(p=0.045),急性生理学和慢性健康评估(APACHE)II 评分更差(p=0.048)。
绝大多数 COVID-19 ARDS 患者均有维生素 D 缺乏症。25-羟维生素 D 状况与临床病程变化无关,而 1,25-二羟维生素 D 水平较低与机械通气时间延长和 APACHE II 评分恶化相关。